Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target

Stock Track11-07

Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.

Despite the price target cut, Chardan maintained its "Buy" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.

The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains "overweight," with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126022241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 23:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126022241","market":"hk","top_or_hot":-1,"title":"Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target","media":"Stock Track","content":"<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Iovance Biotherapeutics Plummets 6.32% as Chardan Slashes Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 23:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.</p>\n\n<p>Despite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.</p>\n\n<p>The move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IOVA","symbol_name":"Iovance Biotherapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126022241","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126022241","pubTimestamp":1762527781,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IOVA":"Iovance Biotherapeutics, Inc."},"translate_title":"股票追踪|Chardan下调目标价，Iovance Biotherapeutics暴跌6.32%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IOVA":1},"content_text":"Shares of Iovance Biotherapeutics, Inc. (IOVA) plummeted 6.32% in early trading on Friday, following a significant price target cut by Chardan Capital Markets. The biotech company's stock took a hit after Chardan lowered its price target from $20 to $17, representing a 15% reduction.\nDespite the price target cut, Chardan maintained its \"Buy\" rating on Iovance Biotherapeutics, indicating a continued belief in the company's long-term potential. However, investors appeared to focus more on the near-term implications of the lowered price target, triggering the sharp decline in IOVA's stock price.\nThe move comes amid a mixed analyst landscape for Iovance Biotherapeutics. According to FactSet, the average analyst rating for IOVA remains \"overweight,\" with a mean price target of $7.75. The significant disparity between Chardan's new target and the average target highlights the wide range of opinions among analysts regarding the company's future prospects. As the trading session progresses, market participants will be closely watching how this news continues to impact IOVA's stock performance.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126022241","isCrawlerRequest":true}